Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | MT-601 |
| Synonyms | |
| Therapy Description |
Limited information is currently available on MT-601, a putative T-cell therapy targeting 6 tumor-associated antigens (Apr 2023). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| MT-601 | MT 601|MT601 | Limited information is currently available on MT-601, a putative T-cell therapy targeting 6 tumor-associated antigens (Apr 2023). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05798897 | Phase I | MT-601 | Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma (APOLLO) | Recruiting | USA | 0 |